A Quercetin/Rg3-Loaded Calcium Phosphate Nanoplatform Alleviates Breast Cancer-Induced Peripheral Hyperalgesia and Enhances Antitumor Immunity.
This study aimed to develop a multifunctional nanoplatform, Rg3-Lip-CaPO4/Quercetin (R-LCP/Q), for integrating antitumor therapy, immune modulation, and cancer pain relief.
R-LCP/Q was constructed by incorporating ginsenoside Rg3 into a lipid-coated calcium phosphate nanoplatform loaded with quercetin (Que). Its physicochemical properties, pH-responsive release, cellular uptake, antitumor activity, Ca2+-associated intracellular effects, immunogenic cell death (ICD), immune modulation, biodistribution, biosafety, and analgesic efficacy were evaluated in vitro and in a 4T1 breast cancer-associated pain model. The involvement of transient receptor potential vanilloid 1 (TRPV1) signalling in analgesia was further assessed using the selective TRPV1 antagonist AMG9810.
R-LCP/Q exhibited pH-responsive degradation and release of Ca2+, Que, and Rg3 under acidic conditions, together with enhanced cellular uptake and tumor-associated accumulation following Rg3 functionalization. R-LCP/Q induced intracellular Ca2+ accumulation, mitochondrial depolarization, ROS generation, and tumor-cell apoptosis; these effects were markedly attenuated by the intracellular Ca2+ chelator BAPTA, supporting a substantial Ca2+-dependent contribution to the cytotoxic response. R-LCP/Q also increased ICD-associated hallmarks and promoted dendritic cells (DCs) maturation. In vivo, R-LCP/Q suppressed tumor growth and was associated with enhanced DCs maturation, increased CD8+T-cell responses, a shift towards an M1-like macrophage phenotype, reduced regulatory T-cell frequencies, and decreased tumor-associated TNF-α and IL-6 levels. R-LCP/Q also alleviated mechanical and thermal hyperalgesia, accompanied by reduced TRPV1 expression in dorsal root ganglia and decreased serum substance P levels; pharmacological TRPV1 blockade with AMG9810 also produced an analgesic response. Short-term haematological, biochemical, histological, and haemocompatibility assessments indicated favourable tolerability.
R-LCP/Q provides preclinical proof of concept for a multifunctional nanotherapeutic strategy integrating tumor suppression, antitumor immune modulation, and cancer pain relief. The findings support further investigation of coordinated tumor-immune-nociceptive regulation as a therapeutic approach for cancer treatment.
R-LCP/Q was constructed by incorporating ginsenoside Rg3 into a lipid-coated calcium phosphate nanoplatform loaded with quercetin (Que). Its physicochemical properties, pH-responsive release, cellular uptake, antitumor activity, Ca2+-associated intracellular effects, immunogenic cell death (ICD), immune modulation, biodistribution, biosafety, and analgesic efficacy were evaluated in vitro and in a 4T1 breast cancer-associated pain model. The involvement of transient receptor potential vanilloid 1 (TRPV1) signalling in analgesia was further assessed using the selective TRPV1 antagonist AMG9810.
R-LCP/Q exhibited pH-responsive degradation and release of Ca2+, Que, and Rg3 under acidic conditions, together with enhanced cellular uptake and tumor-associated accumulation following Rg3 functionalization. R-LCP/Q induced intracellular Ca2+ accumulation, mitochondrial depolarization, ROS generation, and tumor-cell apoptosis; these effects were markedly attenuated by the intracellular Ca2+ chelator BAPTA, supporting a substantial Ca2+-dependent contribution to the cytotoxic response. R-LCP/Q also increased ICD-associated hallmarks and promoted dendritic cells (DCs) maturation. In vivo, R-LCP/Q suppressed tumor growth and was associated with enhanced DCs maturation, increased CD8+T-cell responses, a shift towards an M1-like macrophage phenotype, reduced regulatory T-cell frequencies, and decreased tumor-associated TNF-α and IL-6 levels. R-LCP/Q also alleviated mechanical and thermal hyperalgesia, accompanied by reduced TRPV1 expression in dorsal root ganglia and decreased serum substance P levels; pharmacological TRPV1 blockade with AMG9810 also produced an analgesic response. Short-term haematological, biochemical, histological, and haemocompatibility assessments indicated favourable tolerability.
R-LCP/Q provides preclinical proof of concept for a multifunctional nanotherapeutic strategy integrating tumor suppression, antitumor immune modulation, and cancer pain relief. The findings support further investigation of coordinated tumor-immune-nociceptive regulation as a therapeutic approach for cancer treatment.
Authors
Ji Ji, Sun Sun, Mu Mu, Wang Wang, Hu Hu, Sun Sun, Liao Liao, Liu Liu, Zhao Zhao, Yan Yan, Jiang Jiang, Zhang Zhang
View on Pubmed